NCT05839626 2025-06-12
A Study to Investigate Safety and Efficacy With SAR445514 in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA)
Sanofi
Phase 1/2 Terminated
Sanofi
Prothena Biosciences Ltd.
Oncopeptides AB
GlaxoSmithKline
Prothena Biosciences Ltd.
Prothena Biosciences Ltd.